Skip to content

Rapid or Ultra-rapid Diagnosis of Myocardial Infarction Using High-Sensitivity Cardiac Troponin on Hospital Presentation

Danish Randomized Trial of Rapid or Ultra-rapid Diagnosis of Myocardial Infarction Using High-Sensitivity Cardiac Troponin on Hospital Presentation

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07727135
Acronym
DanRUSH
Enrollment
28000
Registered
2026-07-27
Start date
2026-09-01
Completion date
2029-02-01
Last updated
2026-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease Acute, Cardiovascular Diseases, Coronary Artery Disease, Coronary Syndrome, Acute, Myocardial Infarction

Keywords

Myocardial infarction, Troponin, Biomarker, Clinical assessment, Myocardial injury, Coronary syndrome

Brief summary

People with chest pain are often tested for a heart attack using a blood test called high-sensitivity cardiac troponin (hs-cTn). Traditionally, this blood test is repeated 3 hours after the first sample. Newer guidelines recommend repeating the test after 1 hour instead, which may allow patients to receive a diagnosis and leave the hospital sooner. The purpose of the DanRUSH trial is to compare these two strategies: repeating the blood test after 1 hour versus after 3 hours in adults with suspected acute coronary syndrome. The study will evaluate whether the 1-hour strategy is as safe as the 3-hour strategy while reducing the length of hospital stay. DanRUSH is a nationwide, pragmatic, cluster-randomized trial conducted in emergency- and cardiology departments across Denmark. The results will help determine the best timing for blood testing in patients with suspected heart attack and improve future care for these patients.

Detailed description

Each year, approximately 80,000 individuals present to the Danish healthcare system with chest pain. Of these, around 25,000 are admitted to hospital and approximately 8,000 are diagnosed with acute myocardial infarction. High-sensitivity cardiac troponin (hs-cTn) is the cornerstone biomarker for the diagnosis of myocardial infarction and is essential for the rapid rule-in and rule-out of acute coronary syndromes. Because the diagnosis of myocardial infarction relies not only on troponin concentration but also on changes in troponin levels over time, serial blood sampling is required to distinguish acute myocardial injury from chronic elevations. Advances in hs-cTn assay sensitivity have enabled progressively shorter intervals between serial blood sampling. Traditionally, most emergency departments have used a 0/3-hour algorithm, in which hs-cTn is measured at presentation and again after 3 hours. However, contemporary European guidelines recommend accelerated diagnostic pathways using a 0/1-hour or 0/2-hour algorithm. The primary purpose of the DanRUSH trial is to determine whether shortening the interval between serial hs-cTn measurements from 3 hours to 1 hour is both safe and effective in adults presenting with suspected acute coronary syndrome. The primary safety endpoint is defined as the risk of new (missed or recurrent) myocardial infarction or cardiovascular death after dischage from the index hospitalization -of the 0/1-hour algorithm compared with the 0/3-hour algorithm. Efficacy will be assessed as hospital length of stay, defined as the time from presentation to discharge. The study aims to demonstrate that the 0/1-hour algorithm is non-inferior to the 0/3-hour algorithm with respect to safety while improving efficiency through shorter hospital stays. The study is designed as a nationwide, pragmatic, open-label, stepped-wedge cluster randomized trial. Participating emergency- and cardiology departments in Denmark will sequentially and randomly transition from the conventional 0/3-hour hs-cTn algorithm to the 0/1-hour hs-cTn algorithm until all sites are exposed to the intervention. A study-specific order set in the electronic medical record will ensure the correct timing of serial blood sampling and facilitate identification of study participants. Relevant baseline and outcome information will be obtained from routinely collected data in the electronic medical record and Danish nationwide health registries. The results of DanRUSH are expected to provide definitive randomized evidence regarding the safety and effectiveness of the 0/1-hour hs-cTn algorithm. If the accelerated diagnostic strategy is shown to be safe, it may support broader implementation and improve patient flow by reducing unnecessary hospital stays. Conversely, if safety cannot be confirmed, the study may prevent widespread adoption of an insufficiently validated diagnostic strategy.

Interventions

DIAGNOSTIC_TEST0/3-hour high-sensitivity cardiac troponin algorithm

High-sensitivity cardiac troponin measurements obtained at presentation and 3 hours after the initial sample as part of the conventional diagnostic strategy for suspected acute coronary syndrome.

DIAGNOSTIC_TEST0/1-hour high-sensitivity cardiac troponin algorithm

High-sensitivity cardiac troponin measurements obtained at presentation and 1 hour after the initial sample as part of the accelerated diagnostic strategy for suspected acute coronary syndrome.

Sponsors

Herlev and Gentofte Hospital
Lead SponsorOTHER
Bispeberg and Frederiksberg Hospital
CollaboratorUNKNOWN
Hvidovre and Amager Hospital
CollaboratorUNKNOWN
North Zealand (Hillerød) Hospital
CollaboratorUNKNOWN
Nykøbing Falster Sygehus
CollaboratorUNKNOWN
Gødstrup Hospital
CollaboratorOTHER
Regionshospitalet Viborg, Skive
CollaboratorOTHER
Odense Universitetshospital
CollaboratorUNKNOWN
Esbjerg sygehus
CollaboratorUNKNOWN
Aalborg University Hospital
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

This study is a nationwide, pragmatic, open-label, stepped-wedge cluster randomized trial. Emergency- and cardiology departments serve as the unit of randomization (clusters). All participating clusters initially apply the control strategy, consisting of a 0/3-hour high-sensitivity cardiac troponin algorithm. Clusters subsequently transition sequentially, in a randomized order, to the intervention strategy, consisting of a 0/1-hour high-sensitivity cardiac troponin algorithm, until all clusters have crossed over to the intervention. Individual participants are exposed to only one of the two diagnostic strategies according to the cluster assignment at the time of presentation.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults (≥18 years) presenting with suspected acute coronary syndrome (ACS) with a clinical indication for high-sensitivity cardiac troponin testing

Exclusion criteria

* Age \<18 years. * ST-segment elevation myocardial infarction (STEMI) identified on the presenting electrocardiogram and requiring immediate reperfusion therapy.

Design outcomes

Primary

MeasureTime frameDescription
Safety outcome: New myocardial infarction or cardiovascular deathFrom discharge from the index hospitalization until 30 days after discharge.The risk of new (missed or recurrent) myocardial infarction or cardiovascular death after dischage -of the 0/1-hour algorithm compared with the 0/3-hour algorithm.
Efficacy outcome: Length of hospital stayDuring the index hospitalization (from emergency department presentation until hospital discharge)Length of stay, defined as the time from presentation to the emergency department until discharge from hospital.

Secondary

MeasureTime frameDescription
New myocardial infarction at 12 monthsFrom discharge from the index hospitalization until 12 months after discharge.New myocardial infarction within 12 months following discharge from the index hospitalization, excluding myocardial infarction diagnosed during the index hospitalization.
All-cause mortality30 days and 12 months following dischargeDeath from any cause following discharge from the index hospitalization
Overall myocardial infarction rate30 days and 12 months following dischargeOccurrence of myocardial infarction during follow-up
Diagnostic coronary angiographyDuring the index hospitalization, at 30 days, and at 12 months after the index presentationPerformance of diagnostic coronary angiography following the index presentation
Invasive treatmentDuring the index hospitalization, at 30 days, and at 12 months after the index presentationInvasive coronary treatment, including percutaneous coronary intervention or coronary artery bypass grafting.
Re-presentation to hospital30 days and 12 months following dischargePresentation to the emergency department or hospital following discharge from the index hospitalization
Re-hospitalization30 days and 12 months following dischargeHospital admission following discharge from the index hospitalization
Time to treatment initiationFrom emergency department presentation until initiation of treatment, assessed during the index hospitalization (up to 7 days)Time from presentation to initiation of relevant treatment for acute coronary syndrome

Countries

Denmark

Contacts

CONTACTMajid Afzal, MD
raja.majid.ghafoor.afzal@regionh.dk+45 40 29 26 59
PRINCIPAL_INVESTIGATORManan Pareek, MD, MSc PhD, FAHA, FESC, FACC

Center for Translational Cardiology and Pragmatic Randomized Trials and Department of Cardiology, Herlev and Gentofte Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 7, 2026